In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Gilbert Georg KlammingerDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0001-5358-2751 Hanna WattendorffInstitute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Felix HässlinDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Christoph EckertInstitute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Silke MitschkeInstitute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Stefanie ZimmerInstitute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Meletios P NigdelisDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), 66424 Homburg, Germany.ORCID 0000-0003-3865-6833 Roxana SchwabDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-1489-0011 Walburgis BrennerDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-1511-6212 Annette HasenburgDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-1547-4968 Yaman DegirmenciDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-3713-9490 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
This study assessed the prevalence and clinical relevance of p16
Indexed as
Cell Adhesion MoleculesErb-b2 Receptor Tyrosine KinasesNectinsVaginal NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16FemaleHumansImmunohistochemistryMiddle AgedPrognosisTumor Suppressor Protein p53Biomarkers, TumorCell Adhesion MoleculesCyclin-Dependent Kinase Inhibitor p16ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesNECTIN4 protein, humanNectinsTumor Suppressor Protein p53druggable targetsHER2Nectin-4primary vaginal cancertumor-agnostic therapy
Identifiers
PMID42589670
PMCPMC13467148
What OpenQuestion holds
Textmetadata
Read underepoch 390